Soluble Tumour Necrosis Factor-α Receptor Type 1 (sTNF-R1) in Psoriasis Patients Treated with Psoral
Journal of Pan-Arab League of Dermatologists
Vol. 20, No. 1, February 2009 Page 105- 109
Soluble Tumour Necrosis Factor-α Receptor Type 1 (sTNF-R1) in Psoriasis
Patients Treated with Psoralen plus Ultraviolet A (PUVA)
Marwa S Zaki* and Sherin B ElSayed**
Departments of Dermatology and Venereology* and Microbiology and Immunology**, Faculty of Medicine, Ain
Shams University, Cairo, Egypt.
Abstract
Objectives: To examine the serum concentration of soluble tumour necrosis factor-α receptor type 1 (sTNF-R1) and its relationship with the disease severity in patients with plaque-type psoriasis treated with systemic photochemotherapy (psoralen plus ultraviolet A - PUVA).
Methods: Twenty one patients with plaque-type psoriasis vulgaris were enrolled in the study. The assessment of the severity of skin lesions (using Psoriasis Area and Severity Index - PASI) and sTNF-R1 concentrations were performed at baseline (T 0) and after 24 PUVA irradiations (T 24). Control blood samples were obtained from 12 healthy subjects.
Results: The baseline sTNF-R1 in patients was higher than that in controls (3.32 ± 0.51 vs. 1.40 ± 0.177 ng/ml respectively, P<0.001).The baseline PASI correlated with sTNF-R1 concentrations (R=0.62, P<0.05). The significant decline in sTNF-R1 at T 24 was noticed reaching control values (1.569 ± 0.53 vs. 1.40 ± 0.177 ng/ml respectively, P>0.05).
Conclusion: Soluble TNF-R1 may be a valuable marker of psoriasis severity and efficacy of treatment. We also suggest that the serum level of sTNF-R1 is influenced by PUVA therapy.
Journal of Pan-Arab League of Dermatologists
Vol. 20, No. 1, February 2009 Page 105- 109
Soluble Tumour Necrosis Factor-α Receptor Type 1 (sTNF-R1) in Psoriasis
Patients Treated with Psoralen plus Ultraviolet A (PUVA)
Marwa S Zaki* and Sherin B ElSayed**
Departments of Dermatology and Venereology* and Microbiology and Immunology**, Faculty of Medicine, Ain
Shams University, Cairo, Egypt.
Abstract
Objectives: To examine the serum concentration of soluble tumour necrosis factor-α receptor type 1 (sTNF-R1) and its relationship with the disease severity in patients with plaque-type psoriasis treated with systemic photochemotherapy (psoralen plus ultraviolet A - PUVA).
Methods: Twenty one patients with plaque-type psoriasis vulgaris were enrolled in the study. The assessment of the severity of skin lesions (using Psoriasis Area and Severity Index - PASI) and sTNF-R1 concentrations were performed at baseline (T 0) and after 24 PUVA irradiations (T 24). Control blood samples were obtained from 12 healthy subjects.
Results: The baseline sTNF-R1 in patients was higher than that in controls (3.32 ± 0.51 vs. 1.40 ± 0.177 ng/ml respectively, P<0.001).The baseline PASI correlated with sTNF-R1 concentrations (R=0.62, P<0.05). The significant decline in sTNF-R1 at T 24 was noticed reaching control values (1.569 ± 0.53 vs. 1.40 ± 0.177 ng/ml respectively, P>0.05).
Conclusion: Soluble TNF-R1 may be a valuable marker of psoriasis severity and efficacy of treatment. We also suggest that the serum level of sTNF-R1 is influenced by PUVA therapy.